Branded vs Generic Drugs in Russia and CEE – Expert Insights
Across Russia and former Communist countries in Central and Eastern Europe, the battle for market share is being played out on three fronts between patented drugs, branded and commodity generics.
And it’s not surprising. While consumers prefer the status of innovative patented drugs produced by recognizable Western pharma giants, they are culturally attached to inexpensive, government-subsidized products. And as more and more patented blockbusters go off-patent, branded generics and commodity products alike have gained ground.
Yet the barriers to winning the hearts and wallets of consumers in the region are considerable. Government reimbursement schemes encourage the use of commodity generic brands, which are four times less expensive than patented medications. Legal issues abound, too. Competition between branded and commodity drugs often leads to intellectual property court battles and patent disputes. And in a region well-supported by generics companies, innovative drug brands are often priced out of competition.
Even so, many experts believe that despite the crowded market, there is still room for new entrants in many categories. In Branded vs Generic Drugs in Russia and CEE – expert insights, FirstWord assesses the pharma landscape in CEE countries, including Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia and Slovakia. The report offers an historical perspective cast against economics, cultural preferences and most importantly, the current market climate. Featuring case studies, key insights and interview transcripts with pharmaceutical leaders in the region, the report defines the scope of pharma’s challenges in the region.
The report offers insights into:
The report
SOME OF THE KEY COMPANIES ANALYZED IN THIS REPORT
GlaxoSmithKline
AstraZeneca
Merck
Teva
Gedeon Richter
Sopharma
Chaikapharma
Biovet
And it’s not surprising. While consumers prefer the status of innovative patented drugs produced by recognizable Western pharma giants, they are culturally attached to inexpensive, government-subsidized products. And as more and more patented blockbusters go off-patent, branded generics and commodity products alike have gained ground.
Yet the barriers to winning the hearts and wallets of consumers in the region are considerable. Government reimbursement schemes encourage the use of commodity generic brands, which are four times less expensive than patented medications. Legal issues abound, too. Competition between branded and commodity drugs often leads to intellectual property court battles and patent disputes. And in a region well-supported by generics companies, innovative drug brands are often priced out of competition.
Even so, many experts believe that despite the crowded market, there is still room for new entrants in many categories. In Branded vs Generic Drugs in Russia and CEE – expert insights, FirstWord assesses the pharma landscape in CEE countries, including Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia and Slovakia. The report offers an historical perspective cast against economics, cultural preferences and most importantly, the current market climate. Featuring case studies, key insights and interview transcripts with pharmaceutical leaders in the region, the report defines the scope of pharma’s challenges in the region.
The report offers insights into:
- The current climate market, broken down by branded and generic sectors
- How innovative pharmaceutical companies can make inroads into the region
The report
- Offers an historical, cultural and economic breakdown of the region
- Reviews which companies are gaining headway, and why
- Includes full transcripts of interviews with key pharmaceutical executives
- Offers case studies from leading companies including Pfizer and Gedeon Richter
SOME OF THE KEY COMPANIES ANALYZED IN THIS REPORT
GlaxoSmithKline
AstraZeneca
Merck
Teva
Gedeon Richter
Sopharma
Chaikapharma
Biovet
INTRODUCTION
Purpose of the report
Geographical coverage
Executive summary
MARKET OVERVIEW
Key branded drug manufacturers
Key generics manufacturers
Historical perspectiverecent material trends and changes
Economic perspectiveregulatory, re-imbursement and other business factors
Cultural perspectiveregional culture as a key factor
Current market position of branded versus generics
KEY INSIGHTS
Selected case studies
Pfizer
Gedeon Richter
Valenta
Novartis Consumer Health
Polfa Warsaw
Novartis Slovakia
Top ten pharmaceutical company in Poland
KEY FINDINGS
CONCLUSIONS
INDEX
Purpose of the report
Geographical coverage
Executive summary
MARKET OVERVIEW
Key branded drug manufacturers
Key generics manufacturers
Historical perspectiverecent material trends and changes
Economic perspectiveregulatory, re-imbursement and other business factors
Cultural perspectiveregional culture as a key factor
Current market position of branded versus generics
KEY INSIGHTS
Selected case studies
Pfizer
Gedeon Richter
Valenta
Novartis Consumer Health
Polfa Warsaw
Novartis Slovakia
Top ten pharmaceutical company in Poland
KEY FINDINGS
CONCLUSIONS
INDEX